The Current Ratio as of December 2024 (TTM) for Recursion Pharmaceuticals, Inc. (RXRX) is 4.35

According to Recursion Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.35. This represents a change of -11.91% compared to the average of 4.94 of the last 4 quarters.

Recursion Pharmaceuticals, Inc. (RXRX) Historical Current Ratio (quarterly & annually)

How has RXRX Current Ratio performed in the past?

The mean historical Current Ratio of Recursion Pharmaceuticals, Inc. over the last ten years is 8.99. The current 4.35 Current Ratio has changed 4.74% with respect to the historical average. Over the past ten years (40 quarters), RXRX's Current Ratio was at its highest in in the June 2021 quarter at 21.92. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Recursion Pharmaceuticals, Inc. (RXRX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Recursion Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Recursion Pharmaceuticals, Inc. (RXRX) Average Current Ratio

How has RXRX Current Ratio performed in the past?

The current Current Ratio of Recursion Pharmaceuticals, Inc. (RXRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Recursion Pharmaceuticals, Inc. (RXRX) Current Ratio vs. Peers

How is RXRX’s Current Ratio compared to its peers?

Recursion Pharmaceuticals, Inc.’s Current Ratio is less than Absci Corporation (5.63), greater than Affimed N.V. (1.93), less than Sana Biotechnology, Inc. (4.47), less than Relay Therapeutics, Inc. (18.42), greater than Immix Biopharma, Inc. (3.47), greater than CNS Pharmaceuticals, Inc. (1.82), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than Freeline Therapeutics Holdings plc (1.95), less than AVROBIO, Inc. (26.17), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Enveric Biosciences, Inc. (5.17), less than CohBar, Inc. (15.69), greater than Ocean Biomedical, Inc. (0.04), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (10.43), less than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than VectivBio Holding AG (9.14),

Build a custom stock screener for Recursion Pharmaceuticals, Inc. (RXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Recursion Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Recursion Pharmaceuticals, Inc. (RXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Recursion Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.